Richard Bruce Brandon

Founder at Immunexpress Pty Ltd.

Health Technology

Commercial Services

Profile

Richard Bruce Brandon is the founder of Immunexpress Pty Ltd., where he currently holds the title of Chief Scientific Officer since 2013.
He is also the founder of Immunexpress, Inc., where he currently holds the title of Chief Scientific Officer since 2010.

Richard Bruce Brandon active positions

Companies	Position	Start
Immunexpress Pty Ltd. Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.	Founder	31/12/2005
Immunexpress, Inc. Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in	Founder	31/12/2009

All active positions of Richard Bruce Brandon

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Richard Bruce Brandon's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Immunexpress Pty Ltd. Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.	Health Technology
Immunexpress, Inc. Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in	Commercial Services